Skip to main content
HomeDrug Comparisons
Drug bottle and Pill

Compare Krazati vs. Lumakras

Head-to-head comparisons of medication uses, side effects, warnings, and more.

  • Krazati (adagrasib)
    Lumakras (sotorasib)
  • Krazati (adagrasib)
    Lumakras (sotorasib)

  • Summary of Krazati vs. Lumakras

    Summary for KRAS G12C inhibitor
    Prescription only

    Krazati (adagrasib) is a KRAS inhibitor that's FDA approved to treat advanced and metastatic non-small cell lung cancer (NSCLC) and colorectal cancer in adults with the KRAS G12C mutation. It’s typically used when previous treatments stop working. This medication is used alone to treat NSCLC. But for colorectal cancer, it's used with Erbitux (cetuximab), an infusion given once a week or every other week. Krazati (adagrasib) is conveniently available as an oral tablet which is taken by mouth twice a day. But it can commonly cause bothersome side effects such as diarrhea, nausea, and fatigue.

    Summary for KRAS G12C inhibitor
    Prescription only

    Lumakras (sotorasib) is a medication that’s used for metastatic non-small cell lung cancer (NSCLC). In particular, it’s used for adults who have a specific mutation called KRAS G12C in their lung cancer. Lumakras (sotorasib) is typically recommended only when first-choice treatment doesn’t work anymore. It can be a convenient option since it’s taken by mouth once a day. But, it commonly causes bothersome side effects, like stomach upset and fatigue.

  • Indications of Krazati vs. Lumakras

    Indications for
    •Locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment
    •Locally advanced or metastatic colorectal cancer with a KRAS G12C mutation, together with Erbitux (cetuximab), after having tried certain previous cancer treatments
    Indications for
    •Metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment

  • Pros and Cons of Krazati vs. Lumakras

    Pros and Const for KRAS G12C inhibitor
    Pros
    •Oral tablet that’s taken by mouth
    •Can be taken with or without food
    •Targeted therapy option for people with NSCLC or colorectal cancer with a KRAS G12C mutation
    Cons
    •Has to be taken twice a day
    •Commonly causes diarrhea, nausea, vomiting, and fatigue
    •Only recommended after other treatments haven’t worked
    Pros and Const for KRAS G12C inhibitor
    Pros
    •Oral medication that’s taken once a day
    •Targeted therapy option for people with metastatic non-small cell lung cancer with a KRAS G12C mutation
    Cons
    •Commonly causes diarrhea, nausea, muscle pain, and fatigue
    •Only recommended after first-choice treatment hasn’t worked

  • Common Side Effects of Krazati vs. Lumakras

    Common Side Effects for
    •Diarrhea (70%)
    •Nausea (69%)
    •Lower blood cell counts (up to 64%)
    •Fatigue (59%)
    •Vomiting (56%)
    •Signs of stress to the liver or kidney on blood tests (up to 52%)
    •Muscle or bone pain (41%)
    •Liver injury (37%)
    •Kidney injury (36%)
    •Shortness of breath (35%)
    •Swelling (32%)
    •Loss of appetite (30%)

    Note: Side effects noted above were reported in studies where Krazati (adagrasib) was used alone for lung cancer.

    Common Side Effects for
    •Diarrhea (42%)
    •Muscle or bone pain (35%)
    •Fatigue (26%)
    •Nausea (26%)
    •Cough (20%)

  • Warnings of Krazati vs. Lumakras

    Common Side Effects for
    •Severe digestive system problems
    •Life-threatening abnormal heart rhythm
    •Liver injury
    •Lung damage
    Common Side Effects for
    •Liver injury
    •Lung damage

  • Prices with our coupons for Krazati vs. Lumakras

    Learn more about Krazati
    Learn more about Lumakras

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.